Evaluation of quality of life improvement in melasma patients, measured by the MELASQoL following the use of a botanical combination based on Bellis perennis, Glycyrrhiza glabra e Phyllanthus emblica.;Avaliação da melhoria na qualidade de vida de portadoras de melasma após uso de combinação botânica à base de Bellis perennis, Glycyrrhiza glabra e Phyllanthus emblica comparado ao da hidroquinona, medido pelo MELASQoL

Surgical and Cosmetic Dermatology

Volumn 3, Issue 3, 2011, Pages 207-212

  Costa, Adilson ^a,b   De Oliveira Pereira, Margareth ^b   Abdalla Moisés, Thaís ^c   Cordero, Tatiana ^d   Dias Silva, Ana Roberta ^e   Amazonas, Fabiana T P ^f   Bentivoglio, Fabíola ^e   Pegas Pereira, Elisangela S ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

^c Estudos da KOLderma Instituto de Pesquisa Clínica Ltda ^*

^d Estudos da KOLderma Instituto de Pesquisa Clínica Ltda   (Brazil)

^e Pesquisa da KOLderma Instituto de Pesquisa Clínica Ltda   (Brazil)

^f Estatística da KOLderma Instituto de Pesquisa Clínica Ltda   (Brazil)

Author keywords

Melasma; Phyllanthus emblica; Quality of life

Indexed keywords

EID: 84862099183     PISSN: 19845510     EISSN: 19848773     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Magalhaes GM, Borges MFM, Oliveira PJV, Neves DR. Lactic acid chemical peel in the treatment of melasma: clinical evaluation and impact on quality of life. Surg Cosmet Dermatol. 2010;2(3):173-9.
2. Miot LDB, Miot HA, Silva MG, Marques MEA. Fisiopatologia do melasma. An Bras Dermatol. 2009; 84(6): 623-35.
3. Bandyopadhyay D. Topical Treatment of Melasma. Indian J Dermatol. 2009;54(4): 303-9.
4. Jadotte YT , Schwartz RA. Melasma: insights and perspectives. Acta Dermatovenerol Croat. 2010;18(2):124-9
5. Scherdin U, Burger A, Bielfeldt S, Filbry A, Weber T, Scholermann A, et al. Skin-lightening effects of a new face care product in patients with melasma. J Cosmet Dermatol. 2008;7(1):68-75.
6. Freitag FM,Cestari TF, Leopoldo LR, Paludo P, Boza JC. Effect of melasma on quality of life in a sample of women living in southern Brazil. J Eur Acad Dermatol Venereol. 2008;22(6):655-62.
7. Cestari TF, Balkrishann R, Weber MB, Prati C, Menegon DB, Mazzzotti NG, et al. Translation and cultural adaptation to Portuguese of a quality of life questionnaire for patients with melasma. Med Cut Iber Lat Am. 2006;34(6):270-4.
8. Cestari TF, Hexsel D, Viegas ML, Azulay L, Hassun K, Almeida ART, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. Br J Dermatol. 2006 Dec;156 (Suppl 1):13-20.
9. Grimes PE. Melasma.Etiologic and therapeutic considerations. Arch Dermatol.1995;131(12):1453-7.
10. Sanchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sanchez JL, Mihm MC Jr. Melasma: a clinical, light microscopic, ultrastructural, and immunoflu-orescence study. J Am Acad Dermatol. 1981;4(6):698-710.
11. Hassan I, Kaur I, Sialy R, Dash RJ. Hormonal milieu in the maintenance of melasma in fertile women. J Dermatol.1998;25(8):510-2.
12. Bolanca I, Bolanca Z, Kuna K, Vukovi A, Tuckar N, Herman R, et al. Chloasma--the mask of pregnancy. Coll Antropol. 2008;32 (Suppl 2):139-41.
13. Muzaffar F, Hussain I, Haroon TS. Physiologic skin changes during pregnancy: a study of 140 cases. Int J Dermatol. 1998;37(6):429-31.
14. Perez M, Sanchez JL, Aquilo F. Endocrinologic profile of patients with idiopathic melasma. J Invest Dermatol. 1993;81(6):543-45.
15. Rendon MI. Utilizing combination therapy to optimize melasma outcomes. J Drugs Dermatol. 2004;3(5 Suppl):S27-34.
16. Rendon M, Berneburg M, Arellano I. Treatment of melasma. J Am Acad Dermatol. 2006;54(5 Suppl 2):272-81.
17. Cestari T, Arellano I, Hexsel D, Ortonne JP, Latin American Pigmentary Disorders Academy. Melasma in Latin America: options for therapy and treatment algorithm. J Eur Acad Dermatol Venereol. 2009;23(7):760-72.
18. Costa A, Moises TA,Cordero T, Alves CRT, Marmirori J. Associação de emblica, licorice e belides como alternativa a hidroquinona no tratamento clínico do melasma. An Bras Dermatol. 2010;85(5): 613-20.
19. Sumitra M, Manikandan P, Gayathri VS, Mahendran P, Suguna L. Emblica officinalis exerts wound healing action through upregulation.of collagen and extracellular signal-regulated kinases (ERK1/2).Wound Repair Regen. 2009;17(1):99-107.
20. Zhu W, Gao J. The use of botanical extracts as topical skin-lightening agents for the improvement of skin pigmentation disorders. J Investig Dermatol Symp Proc. 2008;13(1):20-4.
21. Taylor A, Pawaskar M, Taylor SL, Balkrishnan R, Feldman S R. Prevalence of pigmentary disorders and their impact on quality of life: a prospective cohort study. J Cosmet Dermatol. 2008;7(3):164-8.
22. Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, et al. Development and validation of a health-related quality of life instrument for women with melasma.Br J Dermatol. 2003;149(3):572-7.
23. Grimes P,Nordlund JJ, Pandya AG, Taylor S, Rendon M, Ortonne JP. Increasing our understanding of pigmentary disorders. J Am Acad Dermatol. 2006;54(5 Suppl 2):S255-61.
24. Sampaio SAP, Rivitti EA. Discromias. In: Sampaio SAP, Rivitti EA, editores. Dermatologia. 3 ed. São Paulo, Brasil: Artes Médicas; 2008. p. 369-72.
25. Yokota T, Nishio H, Kubota Y, Mizoguchi M. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigment Cells Res. 1998;11(6):355-61.
26. Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007;20(5):308-13.